Emyria Ltd has released a press release.
MDMA Analogue Development Milestone
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Emyria
- Emyria selected to join Palantirs Foundry Builders Program
- Novel MDMA Analogue Screening Program Advanced
- Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
- MDMA-analogues Show Promise for Parkinsons Disease
- Emyria Engages Calvert Labs for Preclinical CBD studies
Later from Emyria
- Emyria Welcomes Tattarang as Strategic Investor
- Emyria receives $1,162,000 R&D Tax Incentive Refund
- Positive initial MDMA-analogue screening results
- Positive animal data for Emyrias ultra-pure CBD capsule
- Pause in Trading
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria